Study

EORTC-1945

Stereotactic body radiotherapy in addition to standard of care treatment in patients with oligometastatic rare cancers (OligoRARE): a randomized, phase 3, open-label trial.

Study documentation Back to result

Trial Status

Recruiting

Dates

Date of activation: 10-Jun-2021

Data management at EORTC

Yes

Design

Phase 3
Randomized open label

Targeted Sample size

EORTC Groups: 200 - All Groups: 200

Treatment

Radiotherapy

Study Staff

Matthias Guckenberger (Study Coordinator), UniversitaetsSpital Zurich, Zurich
Piet Ost (Study Coordinator), GasthuisZusters Antwerpen - Sint-Augustinus, Wilrijk
Jessica Berger (Clinical Research Associate/Monitor), EORTC Headquarters, Brussels
Enrico Clementel (QART Manager), EORTC Headquarters, Brussels
Corneel Coens (Statistician), EORTC Headquarters, Brussels
Coreen Corning (QART Manager), EORTC Headquarters, Brussels
Shani De Coster (Data Manager), EORTC Headquarters, Brussels
Ruxandra Dionisie (Pharmacovigilance Manager), EORTC Headquarters, Brussels
Nathalie Elaut (Study Designer), EORTC Headquarters, Brussels
Beatrice Fournier (Clinical Scientist), EORTC Headquarters, Brussels
Irina Ghislain (QoL Specialist), EORTC Headquarters, Brussels
Leslie Herman (Regulatory Affairs Manager), EORTC Headquarters, Brussels
Volha Hertsyk (RTQA Fellow), EORTC Headquarters, Brussels
Nitish Jha (Statistical Analyst), EORTC Headquarters, Brussels
Eleni Mandila (Regulatory Affairs Administrator), EORTC Headquarters, Brussels
Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
Felix Oppong (Statistician), EORTC Headquarters, Brussels
Davide Passariello (Project Manager), EORTC Headquarters, Brussels
Valentina Pomella (Clinical Operations Manager), EORTC Headquarters, Brussels
Miguel Remis (Lead CRA), EORTC Headquarters, Brussels
Corinne Sokeng (Statistical Analyst), EORTC Headquarters, Brussels
Luiza Souza (QART Manager), EORTC Headquarters, Brussels
Maarten Spruyt (Study Designer), EORTC Headquarters, Brussels
Eliza Starczewska (Regulatory Affairs Manager), EORTC Headquarters, Brussels
Christine de Balincourt (Lead CRA), EORTC Headquarters, Brussels

Type of cancer

Head and Neck
Melanoma
Soft Tissue and Bone Sarcoma
Solid Tumors, Unspecified
Thyroid
Renal

Participating groups

Recruiting centers

Centre Oscar Lambret (LILLE CEDEX, France)
GasthuisZusters Antwerpen - Sint-Augustinus (Wilrijk, Belgium)
Gustave Roussy (VILLEJUIF CEDEX, France)
Inselspital (Bern, Switzerland)
Institut Jules Bordet (Anderlecht, Belgium)
Istituto Europeo di Oncologia (Milano, Italy)
Maria Sklodowska-Curie National Research Institute of Oncology (Warsaw, Poland)
Royal Marsden Hospital - Chelsea, London (London, United Kingdom)
UHB-Queen Elizabeth Medical Centre (Birmingham, United Kingdom)
UniversitaetsSpital Zurich (Zurich, Switzerland)
Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center (Hamburg, Germany)
Universitair Ziekenhuis Gent (Gent, Belgium)

Centers to be activated

Kliniken Maria Hilf GmbH (Moenchengladbach, Germany)
London Health Sciences Centre (London, Canada)
Medical University Of Gdansk (Gdansk, Poland)
Universita Di Torino - San Giovanni Battista (Torino, Italy)

Protocol summary

http://clinicaltrials.gov/study/NCT04498767

NCT number

NCT04498767